CFO departure
Allogene Therapeutics, Inc. discloses CFO departure: Geoffrey Parker
Allogene Therapeutics, Inc. reported in a Form 8-K filed September 2, 2026 a change involving its Chief Financial Officer, Geoffrey Parker, effective November 6, 2026. The filing's own words are quoted below.
In the filing's words
On August 31, 2026, Geoffrey Parker, the Executive Vice President and Chief Financial Officer and principal financial officer of Allogene Therapeutics, Inc. (the “Company”), provided notice of his retirement from the Company in all capacities, effective November 6, 2026.
Verbatim from sec.gov, Item 5.02. We quote departures; we do not characterize them.
| Company | Allogene Therapeutics, Inc. (ALLO) |
|---|---|
| Event | Departure |
| Outgoing | Geoffrey Parker |
| Effective | November 6, 2026 |
| 8-K filed | September 2, 2026 |
| SEC CIK | 0001737287 |
Allogene Therapeutics, Inc. reported this change in a Form 8-K, Item 5.02, filed September 2, 2026. The filing's own words are quoted above.
Other records naming Geoffrey Parker
1The outgoing officer on this record, matched by name. Career line.
2026-03-12 · 10-K signature
Geoffrey Parker signed Allogene Therapeutics, Inc.'s annual report as Chief Financial Officer ( Principal Financial Officer )
Same industry, September 2026
2Other moves filed that month at companies the roster files under SIC “Biological Products, (No Diagnostic Substances)”.
6 weeks ago· 2026-09-30DepartureTCRX
TScan Therapeutics, Inc. discloses CFO departure: Jason A. Amello
6 weeks ago· 2026-09-28InterimJSPR
Jasper Therapeutics, Inc. names Jeet Mahal interim CFO
Sources
- sec.gov · SEC filing, Item 5.02 · accessed 2026-09-26
Something wrong about Geoffrey Parker? Send a correction with the primary source.